SCHEMBL2073886

SCHEMBL2073886

C=COC(=O)C1(C)COC(C)(C)OC1

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KCNA4 P22459 1/20 0.31
KCNA1 Q09470 1/20 0.31
KCNAB1 Q14722 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7737182 0.81
SCHEMBL10412000 0.81
SCHEMBL23868130 0.75 HSD17B10 (0.42) KCNA4KCNA1KCNAB1
SCHEMBL624962 0.75 FFAR3 (0.37)
SCHEMBL2005167 0.73 FFAR3 (0.36)
SCHEMBL21264369 0.73 KCNA4 (0.31) KCNA4KCNA1KCNAB1
SCHEMBL19516511 0.72
SCHEMBL14713396 0.70 ALDH1A1 (0.33)
SCHEMBL21033826 0.69 TSHR (0.41) KCNA4KCNA1KCNAB1
SCHEMBL26830530 0.69 ATM (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856129-B1 39-DESMETHOXY DERIVATIVES OF RAPAMYCIN BIOTICA TECH LTD (GB) 2014-10-15 EP disclosed
US-8258299-B2 Process for preparation of temsirolimus Chungwa Chemical Synthesis & Biotech Co., Ltd. (TW) 2012-09-04 US disclosed
US-8258299-B2 Process for preparation of temsirolimus Chungwa Chemical Synthesis & Biotech Co., Ltd. (TW) 2012-09-04 US disclosed
US-8008318-B2 39-desmethoxy derivatives of rapamycin BIOTICA TECHNOLOGY LIMITED (GB) 2011-08-30 US disclosed
US-7897608-B2 39-desmethoxy-39-methyl derivatives of rapamycin BIOTICA TECHNOLOGY LIMITED (GB) 2011-03-01 US disclosed
US-20100249415-A1 Process for preparation of temsirolimus CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. (TW) 2010-09-30 US disclosed
US-20100249415-A1 Process for preparation of temsirolimus CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. (TW) 2010-09-30 US disclosed
US-20100081682-A1 39-Desmethoxy Derivatives of Rapamycin BIOTICA TECHNOLOGY LIMITED (GB) 2010-04-01 US disclosed
US-7648996-B2 39-desmethoxy derivatives of rapamycin BIOTICA TECHNOLOGY LIMITED (GB) 2010-01-19 US disclosed
US-20090209572-A1 36-Des(3-Methoxy-4-Hydroxycyclohexyl) 36-(3-Hydroxycycloheptyl) Derivatives of Rapamycin for the Treatment of Cancer and Other Disorders BIOTICA TECHNOLOGY LIMITED (GB) 2009-08-20 US disclosed
WO-2007135397-A1 36 -DES (3 -METHOXY-4 -HYDROXYCYCLOHEXYL) 36 - (3 -HYDROXYCYCLOHEPTYL) DERIVATIVES OF RAPAMYCIN FOR THE TREATMENT OF CANCER AND OTHER DISORDERS BIOTICA TECHNOLOGY LIMITED (GB) 2007-11-29 WO disclosed
EP-1856129-A1 39-DESMETHOXY DERIVATIVES OF RAPAMYCIN Biotica Technology Limited (GB) 2007-11-21 EP disclosed
US-7268144-B2 Regiospecific synthesis of rapamycin 42-ester derivatives WYETH (US) 2007-09-11 US disclosed
US-7268144-B2 Regiospecific synthesis of rapamycin 42-ester derivatives WYETH (US) 2007-09-11 US disclosed
US-20070105888-A1 41-Methoxy isotope labeled rapamycin 42-ester WYETH (US) 2007-05-10 US disclosed
US-20070105888-A1 41-Methoxy isotope labeled rapamycin 42-ester WYETH (US) 2007-05-10 US disclosed
US-7202256-B2 Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779 WYETH (US) 2007-04-10 US disclosed
US-7202256-B2 Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779 WYETH (US) 2007-04-10 US disclosed
WO-2006095185-A1 39-DESMETHOXY DERIVATIVES OF RAPAMYCIN BIOTICA TECHNOLOGY LIMITED (GB) 2006-09-14 WO disclosed
WO-2005105811-A1 REGIOSPECIFIC SYNTHESIS OF RAPAMYCIN 42-ESTER DERIVATIVES WYETH (US) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249415-A1 Process for preparation of temsirolimus RICTOR, MTOR, MLST8 KCNA4 4251/4885KCNA1 4759/4885KCNAB1 3601/4885
US-20100081682-A1 39-Desmethoxy Derivatives of Rapamycin RICTOR, MTOR, MALT1 KCNA4 4076/4885KCNA1 4123/4885KCNAB1 3311/4885
US-20090209572-A1 36-Des(3-Methoxy-4-Hydroxycyclohexyl) 36-(3-Hydroxycycloheptyl) Derivatives of Rapamycin for the Treatment of Cancer and Other Disorders MALT1, RICTOR, HGF KCNA4 4327/4885KCNA1 4649/4885KCNAB1 3613/4885
US-20070105888-A1 41-Methoxy isotope labeled rapamycin 42-ester RICTOR, MTOR, RPTOR KCNA4 4774/4885KCNA1 4731/4885KCNAB1 4078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.